Today: 29 June 2026
Browse Category

NASDAQ:OMCL 9 December 2025 - 28 April 2026

Omnicell Stock Surges After Q1 Earnings Beat and Raised 2026 Profit Outlook

Omnicell Stock Surges After Q1 Earnings Beat and Raised 2026 Profit Outlook

Fort Worth, Texas, April 28, 2026, 10:58 CDT Shares of Omnicell Inc. surged Tuesday, as the medication-management tech firm topped analyst forecasts for both first-quarter earnings and sales, while also boosting its profit target for 2026. The upbeat results fueled momentum for Titan XT, Omnicell’s latest automated dispensing system targeting hospitals and health systems.
28 April 2026
··
Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Health jumped another 8.9% by 10:25 a.m. EDT on Monday, pushing its winning streak further. Omnicell and Privia Health only managed gains of less than 1%. Telehealth stocks like Hims & Hers remain in focus after Yahoo Finance highlighted the company’s 48.3% surge over the past week ahead of its earnings release set for May 11. This shift stands out, given the sector hasn’t shown widespread weakness. In recent healthcare-technology roundups, most of the group surpassed fourth-quarter revenue expectations, but recent analyses divided sharply over names like Hims, Privia, and Omnicell. StockStory noted that the four companies focused on hospitals and clinics beat revenue estimates by 1.8%. IndexBox, in a broader look published Friday, also found seven healthcare-tech firms exceeded estimates, singling out Hims & Hers and Privia for standout performance.
20 April 2026
····
Omnicell (OMCL) Stock Today: Titan XT Launch, New $50 Price Target and What It Means for 2025 Investors

Omnicell (OMCL) Stock Today: Titan XT Launch, New $50 Price Target and What It Means for 2025 Investors

Omnicell, Inc. is back on traders’ radar after a cluster of positive catalysts in late 2025 – a new flagship product, raised full-year guidance, improving technical momentum, and fresh analyst upgrades. As of the afternoon session on December 9, 2025, Omnicell shares trade around $43.98, giving the company a market capitalization of roughly $1.4 billion and a price-to-earnings ratio just above 70 based on trailing earnings. The stock closed at $43.55 on December 8, capping a multi-month rebound from the high-20s in October. ir.omnicell.com
9 December 2025
·

Stock Market Today

  • Ross Stores (NASDAQ:ROST) tops Q1 estimates, outpaces discount peers on revenue
    June 29, 2026, 3:43 PM EDT. Ross Stores (NASDAQ:ROST) pulled in $6.01 billion in revenue for Q1, up 20.6% from a year ago and 6.6% over forecasts, leading discount retail. The off-price chain kept customer traffic strong with sales of excess inventory at deep discounts. CEO Jim Conroy pointed to good execution, marketing, and a boost from tax refund spending. Still, shares of discount retailers dropped about 4.5% after earnings, as investors weighed worries around e-commerce and lower mall traffic. Ross stays focused on its value model as retail faces mixed signals.
Go toTop